We are forging a path to treating Major Depressive Disorder and potential future indications through our clinical program for SANA-013.
1Depression Fact Sheet. World Health Organization 2021, The United Nations, accessed 8 March 2022.
2Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. The Journal of Clinical Psychiatry. 2021 Mar 16;82(2):29169.
3Ettman CK, Cohen GH, Abdalla SM, Sampson L, Trinquart L, Castrucci BC, Bork RH, Clark MA, Wilson I, Vivier PM, Galea S. Persistent depressive symptoms during COVID-19: a national, population-representative, longitudinal study of US adults. The Lancet Regional Health-Americas. 2022 Jan 1;5:100091.
4Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. [published online May 21, 2019] Am J Psychiatry. 2019;176(6):428-438.
5Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250-256.
Attaining the NHL Stanley Cup was everything to Daniel Carcillo. He won two—but at the cost of seven concussions. This led to his early retirement from the sport and crippling symptoms of Traumatic Brain Injury. Psychedelic therapy helped Daniel recover and gave him a new life mission: Empowering others to heal their own mental health challenges through the power of Psychedelics.